Celecoxib decreases post-operative pain and lowers morphine consumption after TKR .
Effects of celecoxib on blood loss, pain, and recovery of function after total knee replacement: A randomized placebo-controlled trial
Acta Orthop. 2007 Oct;78(5):661-750 patients requiring total knee replacement (TKR) were randomized to receive either a placebo, or Celecoxib (200mg) preoperatively and twice daily for 3 weeks postoperatively. The primary outcome examined was perioperative blood loss, and other subjective factors were reviewed. Results demonstrated that Celecoxib does not increase perioperative blood loss, but decreases post-operative pain and opioid consumption.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
